Overview of rationale and clinical trials with signal transduction inhibitors in lung cancer.

abstract：:It has been a challenge to find effective chemotherapeutic treatments for malignant mesothelioma. Over the last several decades numerous single-drug and combination regimens have been examined, but no standard treatment with chemotherapy alone has emerged. Possible explanations for this lack of success are the heterog...

journal_title：Seminars in oncology

authors： Baas P

更新日期：2002-02-01 00:00:00

abstract：:Tamoxifen has been demonstrated to be hepatocarcinogenic in some but not all strains of the laboratory rat and is not a carcinogen in the mouse. To resolve the question of whether tamoxifen is genotoxic in humans, many laboratories have studied its interspecies metabolism and its propensity to form DNA adducts. This r...

journal_title：Seminars in oncology

authors： Tannenbaum SR

更新日期：1997-02-01 00:00:00

abstract：:In vitro data suggest a synergistic antiproliferative effect of different cytokines. In four clinical studies chronic myelogenous leukemia (CML) patients were treated with interferon (IFN)-alpha alone or IFN-alpha combined with either low-dose IFN-gamma or tumor necrosis factor (TNF)-alpha. The best response was achie...

journal_title：Seminars in oncology

authors： Wandl UB,Opalka B,Kloke O,Nagel-Hiemke M,Moritz T,Niederle N

更新日期：1992-04-01 00:00:00

abstract：:Gemcitabine is a novel nucleoside analogue that has demonstrated activity against several solid tumors. A large phase II study has been performed in Europe and Canada with a total enrollment of 161 non-small cell lung cancer patients, 26 of whom were from the Institut Gustave-Roussy. Patient characteristics were the s...

journal_title：Seminars in oncology

authors： Le Chevalier T,Gottfried M

更新日期：1997-04-01 00:00:00

abstract：:Cervical cancer is the second most common malignancy in women and the third most common cause of cancer mortality worldwide. While primary and secondary preventions exist, the lack of widespread adoption leaves the treatment of cervical cancer an important oncologic problem. In this article, the management of early an...

journal_title：Seminars in oncology

authors： Barbera L,Thomas G

更新日期：2009-04-01 00:00:00

abstract：:Carcinoembryonic antigen (CEA) is a glycoprotein that is normally expressed in certain parts of the body and commonly overexpressed in most carcinomas of the colon, rectum, breast, lung, pancreas, and gastrointestinal tract. Increased expression of CEA promotes increased intercellular adhesions, which may lead to meta...

journal_title：Seminars in oncology

authors： Marshall J

更新日期：2003-06-01 00:00:00

abstract：:Alterations in chromatin structure resulting from aberrant DNA methylation and perturbations of the histone code profoundly influence gene expression during pulmonary carcinogenesis. Recent studies indicate that DNA demethylating agents and histone deacetylase (HDAC) inhibitors synergistically induce gene expression a...

journal_title：Seminars in oncology

authors： Schrump DS,Nguyen DM

更新日期：2005-10-01 00:00:00

abstract：:For any tumor to become cancerous, various genetic mutations and biologic alterations must occur in the cell that in combination render it a malignant neoplasm. Small cell lung cancer (SCLC) is a neoplasm associated with several molecular and cellular abnormalities. SCLC is associated with early and frequent metastasi...

journal_title：Seminars in oncology

authors： Sattler M,Salgia R

更新日期：2003-02-01 00:00:00

abstract：:Cisplatin is recognized as an active chemotherapeutic agent in a broad variety of human tumors. The severe emetic effects of cisplatin, however, result in both acute and delayed emesis syndromes causing considerable morbidity. Over the last decade, the standard of therapy for control of cisplatin-induced emesis has be...

journal_title：Seminars in oncology

authors： Perez EA,Hesketh PJ,Gandara DR

更新日期：1991-02-01 00:00:00

abstract：:Many patients with Hodgkin's and non-Hodgkin's lymphoma (NHL) can be cured today with combination chemotherapy and/or radiotherapy. However, for patients with suboptimal responses to initial therapy or for patients with refractory or relapsed disease, salvage therapy alone is usually inadequate to achieve long-term su...

journal_title：Seminars in oncology

authors： Laport GF,Williams SF

更新日期：1998-08-01 00:00:00

abstract：:Spirituality can exert a tremendous impact on ones health and promote recovery from trauma and illness, including cancer. Throughout the history of mankind, spirituality and religion have played a major role in healing a variety of physical and mental illnesses. Cancer is one of the most devastating illnesses, as it a...

journal_title：Seminars in oncology

authors： Torosian MH,Biddle VR

更新日期：2005-04-01 00:00:00

abstract：:The current study was conducted to determine the risk of adverse outcomes among patients with monoclonal gammopathy of undetermined significance (MGUS) of the IgM class. Two hundred thirteen patients with IgM MGUS were identified in southeastern Minnesota from 1960 to 1994. The primary end point was progression to lym...

journal_title：Seminars in oncology

authors： Kyle RA,Therneau TM,Rajkumar SV,Offord JR,Larson DR,Plevak MF,Melton LJ 3rd

更新日期：2003-04-01 00:00:00

abstract：:Stem cell transplantation has been successfully used to treat a wide variety of hematologic malignancies. New and exciting strategies being developed for use in conjunction with transplant will be useful in overcoming tumor resistance. It is now clear that a significant part of the antitumor effect of allogeneic stem ...

journal_title：Seminars in oncology

authors： Margolis J,Borrello I,Flinn IW

更新日期：2000-10-01 00:00:00

abstract：:Oligodendroglial tumors are relatively rare, comprising approximately 5% of all glial neoplasms. Oligodendroglial tumor patients have a better prognosis than those with astrocytic neoplasms, and patients with tumors that contain 1p/19q co-deletions or IDH-1 mutations appear to be particularly sensitive to treatment. I...

journal_title：Seminars in oncology

authors： Jaeckle KA

更新日期：2014-08-01 00:00:00

abstract：:Thrombocytopenia is a significant problem for patients receiving prolonged or aggressive chemotherapy for malignancy. For carboplatin, it is the predominant dose-limiting toxicity and it is cumulative in nature. A number of agents have been evaluated for efficacy in reducing the problem of thrombocytopenia. Some have ...

journal_title：Seminars in oncology

authors： Budd GT,Ganapathi R,Wood L,Snyder J,McLain D,Bukowski RM

更新日期：1999-04-01 00:00:00

abstract：:Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) appears to be one of the most active drugs in the treatment of advanced head and neck cancer. The maximum tolerated dose of paclitaxel in combination with carboplatin is currently being evaluated in phase I/II studies. We designed a phase II study to eval...

journal_title：Seminars in oncology

authors： Fountzilas G,Athanassiadis A,Samantas E,Skarlos D,Kalogera-Fountzila A,Nikolaou A,Bacoyiannis H,Stathopoulos G,Kosmidis P,Daniilidis J

更新日期：1997-02-01 00:00:00

abstract：:The activity of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has been documented in untreated and previously treated metastatic breast cancer, including both patients with anthracycline-resistant disease and those with extensive pretreatment. Such activity has prompted investigations of...

journal_title：Seminars in oncology

authors： Dombernowsky P,Gehl J,Boesgaard M,Jensen TP,Jensen BV

更新日期：1996-02-01 00:00:00

abstract：:This article reviews the associations of cancer with rheumatic diseases. Recent epidemiologic data linking the autoimmune connective tissue diseases with malignancy will be emphasized. Reports linking the occurrence of malignancy with rheumatoid arthritis, systemic lupus erythematosus, idiopathic inflammatory myopathy...

journal_title：Seminars in oncology

authors： Carsons S

更新日期：1997-06-01 00:00:00

abstract：:The Department of Veterans Affairs (VA) has a strong track record providing high-quality, evidence-based care to cancer patients. In order to accelerate discoveries that will further improve care for Veterans with cancer, the VA has partnered with the Center for Translational Data Science at the University of Chicago ...

journal_title：Seminars in oncology

authors： Do N,Grossman R,Feldman T,Fillmore N,Elbers D,Tuck D,Dhond R,Selva L,Meng F,Fitzsimons M,Ajjarapu S,Ayandeh S,Hall R,Do S,Brophy M

更新日期：2019-01-01 00:00:00

abstract：:Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has been shown to be an effective agent in the treatment of metastatic breast carcinoma. This multicenter randomized study compared paclitaxel 175 mg/m2 given as a 3-hour infusion every 3 weeks with mitomycin 12 mg/m2 given as an intravenous infusion ever...

journal_title：Seminars in oncology

authors： Dieras V,Marty M,Tubiana N,Corette L,Morvan F,Serin D,Mignot L,Chazard M,Garet F,Onetto N

更新日期：1995-08-01 00:00:00

abstract：:Inflammatory breast cancer (IBC) is an extremely aggressive disease that progresses rapidly and carries a very grim prognosis. It is characterized by erythema, rapid enlargement of the breast, skin ridging, and a characteristic peau d'orange appearance of the skin secondary to dermal lymphatic tumor involvement. Altho...

journal_title：Seminars in oncology

authors： Singletary SE,Cristofanilli M

更新日期：2008-02-01 00:00:00

abstract：:Organ function preservation in patients with head and neck cancer can be achieved by intensity-modulated radiation therapy (IMRT). Much of the work on the physics of IMRT has been done for currently available IMRT systems. However, clinical data remain scarce. Before IMRT is accepted as a standard of care, more compre...

journal_title：Seminars in oncology

authors： Chao KS,Ozyigit G,Thorsdad WL

更新日期：2003-12-01 00:00:00

abstract：:This paper is designed to provide an introduction to music therapy in the continuum of cancer care. The value and use of music therapy during diagnosis and treatment, palliation, hospice, actively dying, and bereavement have been well documented. The music therapy process will be identified, research will be shared, a...

journal_title：Seminars in oncology

authors： Gallagher LM

更新日期：2011-06-01 00:00:00

abstract：:Traditional cancer diagnostic techniques include assessment of histologic appearance, identification of specific tumor subtypes, tumor grading, assessment of lymph node status, and presence of metastasis. These are useful for initial evaluation, but are limited in their ability to predict response to treatment and/or ...

journal_title：Seminars in oncology

authors： Perez EA,Pusztai L,Van de Vijver M

更新日期：2004-10-01 00:00:00

abstract：:Cyclooxygenase-2 (COX-2) is an enzyme involved in prostaglandin production in pathologic states such as inflammatory processes and cancer. The enzyme is often overexpressed in premalignant lesions and various cancers, including cancer of the lung. Inhibition of this enzyme with selective COX-2 inhibitors was found to ...

journal_title：Seminars in oncology

authors： Komaki R,Liao Z,Milas L

更新日期：2004-02-01 00:00:00

abstract：:Clinical research in the treatment of epithelial ovarian cancer has entered a new phase. A pivotal Gynecologic Oncology Group study demonstrated that paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) plus cisplatin was superior to the previous standard therapy of cyclophosphamide plus cisplatin. Confirma...

journal_title：Seminars in oncology

authors： Ozols RF

更新日期：1997-10-01 00:00:00

abstract：:Significant achievements in the basic sciences have led to a greater knowledge of the underlying signaling pathways in renal cell cancer (RCC), including the mammalian target of rapamycin (mTOR) pathway (phosphoinositide 3-kinase/Akt pathway). The mTOR pathway has a central role in the regulation of cell growth and in...

journal_title：Seminars in oncology

authors： Pantuck AJ,Thomas G,Belldegrun AS,Figlin RA

更新日期：2006-10-01 00:00:00

abstract：:Pancreatic neoplasms are morphologically and genetically heterogeneous and include a wide variety of tumors ranging from benign to malignant with an extremely poor clinical outcome. Our understanding of these pancreatic neoplasms has improved significantly with recent advances in cancer sequencing. Awareness of molecu...

journal_title：Seminars in oncology

authors： Rishi A,Goggins M,Wood LD,Hruban RH

更新日期：2015-02-01 00:00:00

abstract：:Although originally developed as an antitumor agent in the 1970s, dexrazoxane (DEX) is currently used as a cardioprotective agent in combination with doxorubicin (DOX). Due to concerns about anthracycline-induced cardiotoxicity at higher cumulative doses, many investigators have chosen to administer DOX by prolonged i...

journal_title：Seminars in oncology

authors： Synold TW,Tetef ML,Doroshow JH

更新日期：1998-08-01 00:00:00

abstract：:This phase I dose-escalation study was undertaken to determine the maximum tolerated doses of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and ifosfamide that could be administered without growth factors to previously untreated patients with non-small cell lung cancer. Forty patients with advanced n...

journal_title：Seminars in oncology

authors： Shepherd FA,Latreille J,Paul K,Eisenhauer E

更新日期：1996-12-01 00:00:00